Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.

Pharmacokinetics and bioequivalence of generic and branded abiraterone acetate tablet: a single-dose, open-label, and replicate designed study in healthy Chinese male volunteers.

Cancer Chemother Pharmacol. 2018 Dec 10;:

Authors: Wang C, Hu C, Gao D, Zhao Z, Chen X, Hu X, Gong S, Li L, Zhang L

Abstract
PURPOSE: Abiraterone acetate is a highly variable drug and has been approved for the treatment of patients with metastatic castration-resistant prostate cancer in many countries. This study was conducted to compare the pharmacokinetic profile between the test product (abiraterone acetate tablet) and reference product ZYTIGA® (250 mg) mainly.
METHODS: To overcome the high intra-subject variability of abiraterone, a two-sequence and four-period crossover study was designed to assess bioequivalence between the two products in 32 healthy male Chinese subjects under fasting conditions. The plasma concentration of abiraterone was analyzed by a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) assay and the reference-scaled procedure was used to determine bioequivalence for the pharmacokinetics parameters.
RESULTS: The point estimate of geometric mean ratios with 90% confidence interval (CI) of maximum observed concentration (Cmax) and the area under the concentration-time curve (AUC0t) for abiraterone in the test and reference products were 100.19% (90% CI 87.05-115.32%) and 105.99% (90% CI 96.34-116.62%), respectively, and were both within the range of 80.00-125.00%. The 95% confidence upper limit bound for [Formula: see text] was - 0.1079 for Cmax and was - 0.0515 for AUC0t.
CONCLUSIONS: Bioequivalence was demonstrated between the two abiraterone acetate products. The study also confirmed high intra-subject variability, for abiraterone: coefficient of variation (CV, %) of Cmax values for the test and reference products were 40.33% and 46.58%, while for AUC0t were 24.02% and 34.16%, respectively.
TRIAL REGISTRATION: https://ift.tt/1XFGNyx : CTR20170997.

PMID: 30535959 [PubMed - as supplied by publisher]

from PubMed via alexandrossfakianakis on Inoreader https://ift.tt/2QvwvZZ